EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-drug conjugates in breast cancer: redefining targeted therapy

Chenxu Guo, Leif W Ellisen

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci207630 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Chenxu Guo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Breast Neoplasms, Molecular Targeted Therapy. Die Arbeit nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer and redefined the conceptual distinction between targeted therapy and conventional chemotherapy. Originally conceived as “magic bullets” that selectively deliver cytotoxic warheads to antigen-expressing tumor cells, clinical and mechanistic evidence indicates that ADC activity depends on a broader interplay of target-dependent and target-independent mechanisms, including extracellular payload release, bystander killing, off-tumor uptake, and immune modulation. Here, we examine ADCs in breast cancer as a distinct therapeutic paradigm. We discuss how antigen biology, linker chemistry, payload features, and drug-to-antibody ratio collectively determine efficacy, toxicity, and therapeutic index. We then compare currently approved and emerging HER2- and TROP2-directed ADCs, highlighting how differences in linker stability, payload pharmacology, and bystander capacity can affect clinical outcomes in ADCs sharing the same target. We further discuss the biological basis and translational challenges of de novo and acquired resistance related to targets, payloads, and tumor microenvironmental constraints, as well as the implications of these mechanisms for biomarker development, sequencing rationales, and combination strategies with immune checkpoint inhibitors and DNA repair–targeting therapies. Finally, we outline future directions of ADC development, including expansion of the target space, novel payload modalities, and next-generation antibody and conjugation engineering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesBreast NeoplasmsMolecular Targeted TherapyHumansFemaleAnimalsAntigens, NeoplasmErb-b2 Receptor Tyrosine Kinases

Substanzen

ImmunoconjugatesAntigens, NeoplasmErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Mass General Brigham Cancer Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Ludwig Center at Harvard, Boston, Massachusetts, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Guo, C., & Ellisen, L. W. (2026). Antibody-drug conjugates in breast cancer: redefining targeted therapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci207630

Vancouver

Guo C, Ellisen LW. Antibody-drug conjugates in breast cancer: redefining targeted therapy. Journal of Clinical Investigation. 2026. doi:10.1172/jci207630

BibTeX
@article{Guo2026,
  author = {Guo, Chenxu and Ellisen, Leif W},
  title = {Antibody-drug conjugates in breast cancer: redefining targeted therapy},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci207630}
}
Kostenlos starten →